EARLY ACADEMIC PURSUITS
Dr. Tanmoy Bera’s academic journey began with a deep commitment to the pharmaceutical sciences. After completing his M.Pharm and PhD at Jadavpur University, India, he embarked on a career that would span decades. He began his teaching career as a senior lecturer at Pune University (1986-1992) before returning to his alma mater, Jadavpur University, in 1992 as a Reader. His work quickly gained recognition, and by 2005, he was appointed a visiting professor at the University of Dublin, Ireland. In 2006, he became a Professor at Jadavpur University, where he has continued his impactful career.
PROFESSIONAL ENDEAVORS
Throughout his career, Dr. Bera has demonstrated an unyielding focus on advancing nanomedicine, bioenergetics, and plant biotechnology. His research has led to the development of innovative drug delivery systems and therapies, particularly for treating asthma, diabetes, and infectious diseases. His work in developing novel antileishmanial agents and combined drug nanoformulations has significantly advanced the field. His efforts are aimed at improving the therapeutic efficacy of treatments, especially in the areas of metabolic and infectious diseases.
CONTRIBUTIONS AND RESEARCH FOCUS ON MEDICINAL PLANTS
Dr. Bera’s contributions have extended beyond the development of new drugs. His innovative nanoformulations, such as those combining curcumin with andrographolide, curcumin with epigallocatechin gallate, and plant extracts from Pueraria tuberosa and Pterocarpus santalinus, have made a lasting impact on the treatment of diabetes and diabetic nephropathy. These advances in nanomedicine are notable for significantly improving solubility and bioavailability, enhancing therapeutic efficacy compared to free drugs.
IMPACT AND INFLUENCE
Dr. Bera’s work has influenced both academia and industry. He has collaborated with organizations like Organon India and contributed to 91 published journal articles, many of which are indexed in high-impact databases like SCI and Scopus. His research has improved treatments for conditions like asthma, diabetes, and infections, making a tangible difference in the lives of patients.
ACADEMIC CITATIONS AND PUBLICATIONS
Dr. Bera’s research has been widely cited, with a citation index of 2426. He has contributed significantly to the scientific community, with 91 journal publications in prestigious SCI and Scopus-indexed journals. His academic presence is also reflected in his editorial roles, having served on the editorial boards of Frontiers in Pharmaceutical Sciences and Biomedicine and as a guest editor for Elsevier’s nanomedicine journal.
HONORS & AWARDS
- Lifetime Achievement Award in Nanomedicine (Venus International Foundation, 2016)
- Invited Guest Editor for Nanomedicine (Elsevier, 2017)
- Editorial Board Member for Frontiers in Pharmaceutical Sciences and Biomedicine (2017)
- Multiple industry collaborations, including with Organon India for two years.
LEGACY AND FUTURE CONTRIBUTIONS
Dr. Bera’s research legacy is built on advancing the understanding and treatment of metabolic diseases, infectious diseases, and drug resistance. His ongoing work promises to further revolutionize nanomedicine and plant biotechnology. As he continues to mentor future generations of scientists, his influence in both academic research and real-world applications remains immense.
FINAL NOTE
Dr. Tanmoy Bera’s career is a testament to the power of scientific innovation and dedication. His work has brought new treatments to the forefront of modern medicine and has paved the way for further research into nanomedicine and bioenergetics. He continues to shape the future of pharmaceutical sciences, ensuring his legacy endures in both the academic and medical communities.
NOTABLE PUBLICATIONS
Shellac and locust bean gum coacervated curcumin, epigallocatechin gallate nanoparticle ameliorates diabetic nephropathy in a streptozotocin-induced mouse model
- Authors: Bhutia, G.T., De, A.K., Bhowmik, M., Bera, T.
- Journal: International Journal of Biological Macromolecules
- Year: 2024
VALIDATION, STABILITY STUDIES, AND SIMULTANEOUS ESTIMATION OF CO-ENCAPSULATED CURCUMIN, EPIGALLOCATECHIN GALLATE NANOFORMULATION BY RP-HPLC METHOD
- Authors: Bhutia, G.T., De, A.K., Bera, T.
- Journal: International Journal of Applied Pharmaceutics
- Year: 2022
Assessment of quality of life among advanced ovarian cancer patients in a tertiary care hospital in India
- Authors: Sarkar, S., Sahoo, P.K., Pal, R., Bera, T., Nasare, V.D.
- Journal: Supportive Care in Cancer
- Year: 2022
Analytical method development, validation and stability studies by RP-HPLC method for simultaneous estimation of andrographolide and curcumin in co-encapsulated nanostructured lipid carrier drug delivery system
- Authors: De, A.K., Bera, T.
- Journal: International Journal of Applied Pharmaceutics
- Year: 2021
Therapeutic potential of andrographolide-loaded nanoparticles on a murine asthma model
- Authors: Chakraborty, S., Ehsan, I., Mukherjee, B., Debnath, M.C., Bera, T.
- Journal: Nanomedicine: Nanotechnology, Biology, and Medicine
- Year: 2019